Clinical Trial Update: A Randomised, Open-label, Multicentre Phase III Clinical Study to Evaluate the Efficacy and Safety of JS105 Combined With Dalpiciclib and Fulvestrant Compared With Dalpiciclib and Fulvestrant in Patients With PIK3CA-mutated, HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer. [Phase 3]

View source ↗

Summary

Clinical trial update for a Phase III randomized study evaluating JS105 with dalpiciclib and fulvestrant versus dalpiciclib and fulvestrant in patients with PIK…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Dalpiciclib (dalpiciclib)
• Fulvestrant (fulvestrant)
• JS105 (JS105)

Snippet

Sponsor: Risen (Suzhou) Pharma Tech Co., Ltd. | Conditions: Breast Cancer | Phase 3 | Status: RECRUITING